Cyril Hanin, Paloma Torres, Isabelle Millet, Joana Matos, Cora Cravero, Marianna Giannitelli, Anne-Sophie Pellen, Hugues Pellerin, Charline Grossard, Ingrid Zammouri, Astrid De Foucaud, Claudine Laurent-Levinson, David Cohen
{"title":"神经发育障碍伴多维损害的遗传异常","authors":"Cyril Hanin, Paloma Torres, Isabelle Millet, Joana Matos, Cora Cravero, Marianna Giannitelli, Anne-Sophie Pellen, Hugues Pellerin, Charline Grossard, Ingrid Zammouri, Astrid De Foucaud, Claudine Laurent-Levinson, David Cohen","doi":"10.1007/s12031-025-02424-6","DOIUrl":null,"url":null,"abstract":"<div><p>Objectives: Many children with neurodevelopmental disorders (NDD) show complex, multidimensional impairments meeting criteria for multiple NDD, yet remain “diagnostically homeless” as DSM-5 lacks a Multidimensional Impairment (MDI) category. We investigated the prevalence of genetic abnormalities in such complex NDD cases. Methods:Between 2017 and 2019, we diagnosed MDI in 666 patients. Among them, 122 (18%) underwent genetic assessment (DNA microarrays, karyotype, gene panels, FISH, FMR1 testing, exome/genome sequencing). We used univariate analyses and clustering to explore associations between clinical dimensions and genetic findings. Results: Genetic abnormalities were identified in 78 patients. Of these:</p><ol>\n <li>\n <span>(1)</span>\n \n <p>41 had known abnormalities usually linked to complex NDD (e.g., del22q11.2);</p>\n \n </li>\n <li>\n <span>(2)</span>\n \n <p>16 had mutations associated with severe ASD/ID (e.g., <i>GRIA3</i> on Xq25);</p>\n \n </li>\n <li>\n <span>(3)</span>\n \n <p>11 showed novel abnormalities not previously linked to NDD (e.g., duplication Xq21.1 including <i>POU3F4</i>);</p>\n \n </li>\n <li>\n <span>(4)</span>\n \n <p>10 had variants of uncertain significance.</p>\n \n </li>\n </ol><p> Depending on classification, prevalence ranged from 47% (57/122, definite or predisposition) to 64% (78/122, including uncertain/possible pathogenic variants). Neither clinical dimensions nor severity clusters were associated with the presence of genetic abnormalities. Conclusion:Despite a referral bias toward severe cases, the high rate of genetic findings in this cohort underscores the need for more systematic genetic testing in complex NDD with multidimensional impairment.</p></div>","PeriodicalId":652,"journal":{"name":"Journal of Molecular Neuroscience","volume":"75 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genetic Abnormalities in Neurodevelopmental Disorders with Multidimensional Impairment\",\"authors\":\"Cyril Hanin, Paloma Torres, Isabelle Millet, Joana Matos, Cora Cravero, Marianna Giannitelli, Anne-Sophie Pellen, Hugues Pellerin, Charline Grossard, Ingrid Zammouri, Astrid De Foucaud, Claudine Laurent-Levinson, David Cohen\",\"doi\":\"10.1007/s12031-025-02424-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Objectives: Many children with neurodevelopmental disorders (NDD) show complex, multidimensional impairments meeting criteria for multiple NDD, yet remain “diagnostically homeless” as DSM-5 lacks a Multidimensional Impairment (MDI) category. We investigated the prevalence of genetic abnormalities in such complex NDD cases. Methods:Between 2017 and 2019, we diagnosed MDI in 666 patients. Among them, 122 (18%) underwent genetic assessment (DNA microarrays, karyotype, gene panels, FISH, FMR1 testing, exome/genome sequencing). We used univariate analyses and clustering to explore associations between clinical dimensions and genetic findings. Results: Genetic abnormalities were identified in 78 patients. Of these:</p><ol>\\n <li>\\n <span>(1)</span>\\n \\n <p>41 had known abnormalities usually linked to complex NDD (e.g., del22q11.2);</p>\\n \\n </li>\\n <li>\\n <span>(2)</span>\\n \\n <p>16 had mutations associated with severe ASD/ID (e.g., <i>GRIA3</i> on Xq25);</p>\\n \\n </li>\\n <li>\\n <span>(3)</span>\\n \\n <p>11 showed novel abnormalities not previously linked to NDD (e.g., duplication Xq21.1 including <i>POU3F4</i>);</p>\\n \\n </li>\\n <li>\\n <span>(4)</span>\\n \\n <p>10 had variants of uncertain significance.</p>\\n \\n </li>\\n </ol><p> Depending on classification, prevalence ranged from 47% (57/122, definite or predisposition) to 64% (78/122, including uncertain/possible pathogenic variants). Neither clinical dimensions nor severity clusters were associated with the presence of genetic abnormalities. Conclusion:Despite a referral bias toward severe cases, the high rate of genetic findings in this cohort underscores the need for more systematic genetic testing in complex NDD with multidimensional impairment.</p></div>\",\"PeriodicalId\":652,\"journal\":{\"name\":\"Journal of Molecular Neuroscience\",\"volume\":\"75 4\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Molecular Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12031-025-02424-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12031-025-02424-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Genetic Abnormalities in Neurodevelopmental Disorders with Multidimensional Impairment
Objectives: Many children with neurodevelopmental disorders (NDD) show complex, multidimensional impairments meeting criteria for multiple NDD, yet remain “diagnostically homeless” as DSM-5 lacks a Multidimensional Impairment (MDI) category. We investigated the prevalence of genetic abnormalities in such complex NDD cases. Methods:Between 2017 and 2019, we diagnosed MDI in 666 patients. Among them, 122 (18%) underwent genetic assessment (DNA microarrays, karyotype, gene panels, FISH, FMR1 testing, exome/genome sequencing). We used univariate analyses and clustering to explore associations between clinical dimensions and genetic findings. Results: Genetic abnormalities were identified in 78 patients. Of these:
(1)
41 had known abnormalities usually linked to complex NDD (e.g., del22q11.2);
(2)
16 had mutations associated with severe ASD/ID (e.g., GRIA3 on Xq25);
(3)
11 showed novel abnormalities not previously linked to NDD (e.g., duplication Xq21.1 including POU3F4);
(4)
10 had variants of uncertain significance.
Depending on classification, prevalence ranged from 47% (57/122, definite or predisposition) to 64% (78/122, including uncertain/possible pathogenic variants). Neither clinical dimensions nor severity clusters were associated with the presence of genetic abnormalities. Conclusion:Despite a referral bias toward severe cases, the high rate of genetic findings in this cohort underscores the need for more systematic genetic testing in complex NDD with multidimensional impairment.
期刊介绍:
The Journal of Molecular Neuroscience is committed to the rapid publication of original findings that increase our understanding of the molecular structure, function, and development of the nervous system. The criteria for acceptance of manuscripts will be scientific excellence, originality, and relevance to the field of molecular neuroscience. Manuscripts with clinical relevance are especially encouraged since the journal seeks to provide a means for accelerating the progression of basic research findings toward clinical utilization. All experiments described in the Journal of Molecular Neuroscience that involve the use of animal or human subjects must have been approved by the appropriate institutional review committee and conform to accepted ethical standards.